Atanasio
Pandiella Alonso
Universidad de Salamanca
Salamanca, EspañaPublicacions en col·laboració amb investigadors/es de Universidad de Salamanca (129)
2024
-
Multiple mechanisms contribute to acquired TRAIL resistance in multiple myeloma
Cancer Cell International, Vol. 24, Núm. 1
-
Ocoxin Oral Solution Triggers DNA Damage and Cell Death in Ovarian Cancer
Nutrients, Vol. 16, Núm. 15
-
Peptidylarginine deiminase 3 modulates response to neratinib in HER2 positive breast cancer
Oncogenesis, Vol. 13, Núm. 1
-
Synergistic effects of medicinal plants in combination with spices from algeria: Anticancer, antiangiogenic activities, and embrytoxicity studies
Journal of Ethnopharmacology, Vol. 330
-
Trastuzumab deruxtecan in breast cancer
Critical Reviews in Oncology/Hematology, Vol. 198
2023
-
An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugs
Cancer Letters, Vol. 554
-
Etiopathogenic role of ERK5 signaling in sarcoma: prognostic and therapeutic implications
Experimental and Molecular Medicine, Vol. 55, Núm. 6, pp. 1247-1257
2022
-
Immune Checkpoint Inhibitors and RAS–ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma
Biomolecules, Vol. 12, Núm. 11
-
Novel adcs and strategies to overcome resistance to anti-her2 adcs
Cancers, Vol. 14, Núm. 1
2020
-
Integrin ανβ6 Protein Expression and Prognosis in Solid Tumors: A Meta-Analysis
Molecular Diagnosis and Therapy, Vol. 24, Núm. 2, pp. 143-151
-
Letter to the editor: What about incorporating selenium in the therapeutic regimen of SARS-CoV-2?
EXCLI Journal
-
Medicinal Plants as Sources of Active Molecules Against COVID-19
Frontiers in Pharmacology, Vol. 11
-
What about incorporating vitamins D and C supplementation in the prevention and treatment of COVID-19? The immune response pathway
Mediterranean Journal of Nutrition and Metabolism
2019
-
A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors
Frontiers in Immunology, Vol. 10
-
Bryonia dioica aqueous extract induces apoptosis and G2/M cell cycle arrest in MDA-MB 231 breast cancer cells
Molecular Medicine Reports, Vol. 20, Núm. 1, pp. 73-80
-
Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study
Breast Cancer Research and Treatment, Vol. 174, Núm. 3, pp. 693-701
-
Expression of MHC class I, HLA-A and HLA-B identifies immune-activated breast tumors with favorable outcome
OncoImmunology, Vol. 8, Núm. 10
-
MEK5 promotes lung adenocarcinoma
The European respiratory journal
-
Paclitaxel-trastuzumab mixed nanovehicle to target HER2-overexpressing tumors
Nanomaterials, Vol. 9, Núm. 7
-
Prognostic value of receptor tyrosine kinase-like orphan receptor (ROR) family in cancer: A meta-analysis
Cancer Treatment Reviews, Vol. 77, pp. 11-19